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ABSTRACT  
Background: Accelerated biological and functional aging is common in fibrotic interstitial lung 
disease (ILD); however, their impact on adverse health outcomes has not been evaluated in this 
population.  
Methods: Patients were prospectively recruited from a specialized ILD clinic. Functional aging was 
determined by the frailty index (FI), and biological age by measurement of absolute telomere length 
(aTL) from patients’ peripheral blood leukocytes. Adverse health outcomes included health-related 
quality of life (St George’s Respiratory Questionnaire), number and length of respiratory and non-
respiratory hospitalisations, medication tolerability, and time to death or lung transplantation. 
Multivariable models were used to determine the risks and rates of adverse health outcomes 
associated with the FI and aTL.  
Results: 540 patients with fibrotic ILD, including 100 with idiopathic pulmonary fibrosis (IPF), 
provided 749 FI assessments, with 189 patients providing blood samples. The FI was strongly 
associated with quality of life, rate of hospitalisation, time to hospital discharge, and mortality, 
including with adjustment for age, sex, disease severity, and IPF diagnosis. Mortality prognostication 
was improved by the addition of the FI to commonly used clinical parameters and previously 
validated composite indices. Conversely, aTL was not associated with most adverse health 
outcomes. The effect of chronological age on outcomes was mediated primarily by the FI and to a 
lesser extent by aTL.  
Conclusions: Functional aging is associated with adverse health outcomes in patients with fibrotic 
ILD, indicating the need for consideration of the individual functional age into clinical decision-
making.  
  
INTRODUCTION 
Interstitial lung disease (ILD) is an increasingly common group of inflammatory and fibrotic disorders 
that damage the lung parenchyma. Fibrotic ILDs are typically associated with exercise limitation, 
reduced quality of life and early mortality. Many fibrotic ILDs, including idiopathic pulmonary fibrosis 
(IPF), increase in incidence with age and are thus frequently associated with comorbidities that 
increase the complexity of management and place substantial burden on the healthcare system.[1-
3]  
The time-dependent gradual loss of physical and social functioning with aging is typically accelerated 
in patients with chronic diseases,[4] and many cellular and molecular hallmarks of aging are 
frequently and prematurely observed in patients with fibrotic ILDs.[5, 6] The accelerated functional 
aging associated with fibrotic ILD is best represented by the concept of frailty, defined as the 
accumulation of age- and health-related deficits across physical, psychological, and social systems.[4, 
7-9] This diminished physiological reserve and increased vulnerability to minor stressors is common 
in fibrotic ILD,[10-12] and may expose these patients to adverse health outcomes. Frailty has been 
associated with a higher risk of death in the general population,[4, 9] in patients with chronic 
obstructive pulmonary disease (COPD),[13] and in lung transplant candidates.[14] However, the risks 
associated with frailty as a proxy of accelerated functional aging, and different impacts of functional, 
biological and chronological aging in patients with fibrotic ILD have not been evaluated.  
The goal of this study was therefore to determine the impact of functional aging (i.e., frailty) on 
mortality, hospitalisations, and quality of life in a large cohort of patients with fibrotic ILD. We used 
peripheral blood leukocyte telomere length as a proxy of biological aging to further determine the 
specific role of functional aging compared to biological and chronological aging. Our pre-specified 
central hypothesis was that frailty would independently predict adverse health outcomes in fibrotic 
ILD, thus indicating the central importance of functional aging in the management of these patients.  
METHODS 
Study population and measurements 
Consecutive patients with a multidisciplinary diagnosis of fibrotic ILD were recruited from an 
outpatient ILD referral centre between July 2014 and July 2017, including patients with idiopathic 
pulmonary fibrosis (IPF),[15] chronic hypersensitivity pneumonitis (HP),[16] unclassifiable ILD, and 
connective tissue disease (CTD)-associated ILD.[17] All patients provided informed written consent 
(UBC ethics board approval H10-03099).  
Functional aging: The Frailty Index 
Frailty, representing functional aging, was measured using a self-reported Frailty Index (FI) consisting 
of 42 deficits, including 19 comorbidities and 23 deficits related to independence and self-care. 
Patients confirmed or denied the presence of each equally weighted deficit, as previously 
described.[18] The FI is calculated as the proportion of items present divided by the total number of 
surveyed items, expressed as a continuous variable between 0 and 1. Surveyed deficits without a 
patient response were removed from the denominator (1.5% of all surveyed items). Frailty was 
defined as FI >0.21.[4]  Data from the Canadian Study of Health and Aging show a submaximal limit 
of the FI of 0.65 (+/- 0.02) in a general outpatient population, beyond which mortality is 
imminent.[19] We previously demonstrated that the FI has good internal consistency in fibrotic ILD 
and that frailty is more prevalent in patients with fibrotic ILD than in the general population.[10] The 
items within the FI were subcategorized into 19 items related to comorbidities (Co-FI), and 23 items 
related to independence and self-care (I&SC-FI). The FI was completed at study entry, including both 
incident and prevalent diagnoses of ILD, and during follow-up when patients returned for routine 
clinical assessments. FI that were completed within 6 months of a preceding FI were excluded from 
analysis, in order to avoid overlapping observation periods.  
Biological aging: Leukocyte telomere length  
Blood leukocyte telomere length was measured in a random subgroup of consecutively recruited 
patients who consented to donate blood samples. We applied a modified version of the Cawthon 
method for measurement of absolute telomere length (aTL) using quantitative real-time polymerase 
chain reaction.[20, 21] A detailed description is provided in the supplement.  
Outcome assessments 
Health-related quality of life was measured using the St George’s Respiratory Questionnaire (SGRQ) 
without any modification. This 50-item patient-reported questionnaire was specifically developed 
for respiratory diseases,[22] is frequently used in patients with ILD, and has recently been validated 
in connective tissue disease-associated ILD.[23, 24] The SGRQ includes three domains relating to 
symptoms, activity, and impact, as well as a total score that ranges from 0-100 with a higher score 
indicating worse quality of life. Non-elective respiratory-related hospitalisations, non-respiratory-
related hospitalisations, and cumulative number of days admitted to hospital within 6 months of 
each frailty assessment were identified from the medical record. Patients completing more than one 
frailty assessment contributed multiple non-overlapping 6-month follow-up intervals during the 
study period. Time to death, lung transplantation, or censoring was calculated from the date of the 
first frailty assessment. The medical record was used to identify adverse effects related to prevalent 
ILD pharmacotherapy that occurred within 6 months of each frailty assessment. Medication adverse 
reactions (MAR) were defined according to the World Health Organization (WHO) as an unintended 
or noxious response to a drug that occurs at doses normally used in humans.[25] MARs were 
specified as effects that resulted in a dose reduction, purposeful treatment interruption for longer 
than one day, or treatment discontinuation for more than 14 days.[25]  
Other measurements 
Demographics and baseline characteristics were collected from the clinical record, including age, 
sex, body mass index, and smoking history. Pulmonary function tests were performed using 
established protocols.[26, 27] All clinical measurements were completed within 3 months of the 
frailty assessment.  
Statistical analysis 
Data structure was hierarchical with multiple FI and covariate measurements per patient at time 
intervals of 6 months or more. The primary mortality endpoint was time to the composite of death 
or lung transplantation. Other outcomes were assessed within the 6-month time periods after every 
FI assessment. Time to death or lung transplantation and time to hospital discharge were each 
analysed using Cox proportional hazards regression models. Discrimination was measured using the 
Harrell’s C-statistic. In a pre-specified sensitivity analysis we used competing risk regression 
according to Fine and Gray,[28] with death and lung transplantation as competing risks. Rate of 
hospitalisations, probabilities for MAR, and associations with SGRQ were modelled using generalized 
mixed effects models accounting for intra-patient correlation with random intercepts. Fixed effects 
included FI, TL, and potential confounders with either conceptual importance (age, sex) or a 
statistically relevant relationship to the outcome. These models were fitted for linear, binomial and 
Poisson distribution families according to the outcomes of interest. Mediation of the effect of 
chronological age on adverse health outcomes by either functional age (FI) or by biological age (aTL) 
was explored with causal mediation analysis (CMA). Estimates for the average causal mediation 
effect/average total effect for an increase in chronological age by one year were reported. A 
directed acyclic graph is provided in the supplement (Figure S1). Model specification, assumption 
testing and specific statistical programs used are reported in the supplement. A two-sided p<0.05 
was used to indicate statistical significance for all comparisons. Data were analyzed using R version 
3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).[29]  
RESULTS 
Patient characteristics 
The 540 patients provided a total of 749 frailty assessments with a median (IQR) interval of 10.8 (6.2-
17.7) months between assessments in patients who completed more than one frailty questionnaire 
(Table 1). Diagnoses included IPF (n=100), systemic sclerosis-associated ILD (n=109), other CTD-ILD 
(n=118), chronic HP (n=47), and 39 with other ILDs. A confident diagnosis was unable to be assigned 
for 127 patients who were designated as unclassifiable ILD. At baseline, 42% of men and 56% of 
women were classified as frail. The median (IQR) FI for the entire cohort was 0.214 (0.095-0.333), 
the Co-FI was 0.158 (0.052-0.211), and the I&SC-FI was 0.261 (0.087-0.435). Women had accelerated 
functional aging with higher frailty scores compared to men, as did patients with non-IPF ILDs 
compared to patients with IPF (Table 2). 
Health-related quality of life  
Frailty severity was correlated with worse quality of life on unadjusted analysis and with adjustment 
for age, sex, ILD severity, and IPF diagnosis (Table 3). This was present for pairwise associations of all 
frailty measures (FI, Co-FI, I&SC-FI) with all SGRQ domains.  
Hospitalisations 
There were 231 non-elective hospitalisations within the 749 observation periods from the 540 
patients, including 131 respiratory-related hospitalisations. Over the entire study period, 459 
patients had no hospitalisations and 81 patients had between 1 and 5 hospitalisations. The median 
cumulative number of days admitted to hospital within 6 months of frailty assessment was 5 (2-14) 
among those periods with at least one hospitalisation. Patients with more severe frailty had a higher 
rate of all-cause and respiratory-related hospitalisations and longer time to hospital discharge on 
unadjusted and adjusted analysis, with these associations primarily driven by the I&SC-FI component 
of frailty (Table 3 and Figure 1). On unadjusted analysis, frail patients had more than double the rate 
of all-cause and respiratory-related hospitalisations with significantly greater risk for prolonged 
hospital stay. All but the association with respiratory-related hospitalisations remained statistically 
significant on adjusted analysis.  
Survival 
Over the median follow-up time of 17 (9.2-26.7) months, 81 patients died and 14 patients 
underwent lung transplantation. Patients with advanced functional aging hence classified as frail had 
significantly worse 1-/2-/3-year transplant-free survival of 86%/77%/73% compared to non-frail 
patients (94%/91%/87%, p<0.001; Figure 2). Higher FI and I&SC-FI were associated with time to 
death or transplant on unadjusted analysis and with adjustment for age, sex, IPF diagnosis, and ILD 
severity (Table 3), and with adjustment for the composite Gender Age Physiology (GAP)-ILD Index 
(data not shown).[30] The prognostic ability of the models increased substantially when FI was 
added to age and sex, with a  marginal and probably clinically non-relevant increase of the C-index 
when FI was added to a multivariate model including age, sex, ILD severity, and IPF diagnosis (Table 
4). Consistent results were obtained using a pre-specified sensitivity analysis that considered death 
and lung transplantation as competing risks. The submaximal limit of the FI was 0.67, corresponding 
to the 99th-percentile. Stratification by IPF and CTD-ILD diagnoses revealed largely unchanged 
findings (data not shown). 
Medication adverse reactions  
The 239 patients (44%) treated with ILD-specific medications had a higher FI (0.244 versus 0.191, 
p=0.005) compared to untreated patients. In patients already on ILD-specific medication at the time 
of assessment, future dose reductions and treatment discontinuation both occurred in 3% of 
immunosuppressive treatments within 6 months of the FI assessment, whereas 12% of anti-fibrotic 
therapies resulted in MAR leading to treatment discontinuation. Within the subsequent 6-month 
observation period after frailty assessment, patients classified as frail were more likely to have a 
MAR resulting in dose reductions on unadjusted analysis (odds ratio 11.3, 95%-CI 1.01-127, 
p=0.049); however, this analysis was underpowered and this association lost statistical significance 
with adjustment for age, sex, ILD severity, and IPF diagnosis (odds ratio 7.03, 95%-CI 0.62-79.8, 
p=0.12).  
Impact of telomere length on outcomes 
Baseline characteristics of the telomere subgroup were similar to the full cohort (Table S2). Absolute 
TL as a proxy of biological aging showed no correlation with functional aging (FI) in the sub-cohort of 
the 189 patients who had provided a blood sample at the time of frailty assessment (r=0.04, p=0.57), 
although there was moderate correlation of chronological and biological age (r=-0.36, p<0.001). 
Absolute TL did not predict survival or quality of life on unadjusted analysis; however, there was a 
6% (IRR 95%-CI 0.99-1.12, p=0.056) and 9% (IRR 95%-CI 1.01-1.17, p=0.03) higher rate of all-cause 
and respiratory-related hospitalisations for each 10kpb/genome decrease in aTL. These associations 
were not maintained with adjustment for age and sex (Table 5).  
Causal mediation analysis 
An exploratory causal mediation analysis showed that the overall effect of chronological age on 2-
year survival (per 10-year increase OR 2.41 [95%-CI 1.37-7.09], p=0.01) was mediated largely by 
functional age (FI indirect/total effect 53%), whereas a model including aTL as mediator showed that 
a smaller fraction of the effect of chronological age on outcomes was mediated by biological age 
(aTL indirect/total effect 31%). Similarly, the increased rate of all-cause hospitalisations in older 
patients (per 10-year increase IRR 1.35 [95%-CI 1.04 to 1.77], p=0.03) was mainly mediated by 
functional age (FI indirect/total effect 43%), and to a lesser extent by biological age (aTL 
indirect/total effect 22%). Conversely, the effect of chronological age on respiratory-related 
hospitalisations (per 10-year increase IRR 1.54 [95%-CI 1.08 to 2.26], p=0.02) was primarily mediated 
by biological age (aTL indirect/total effect 45% versus FI indirect/total effect 13%). Robustness of the 
models to unmeasured confounding between the mediator and the outcome was confirmed as 
previously suggested and described in the supplementary methods.[31]  
DISCUSSION 
We evaluated chronological, functional, and biological aging in this large prospective cohort of 
patients with fibrotic ILD to show that frailty predicts adverse health outcomes and is a clinically 
relevant concept representing functional age in this population. Beyond its significant association 
with mortality, we show that frailty is associated with worse quality of life, a twofold higher rate of 
hospitalisations, and longer hospital stay. Although underpowered, our findings also suggest that 
frailty may predict medication side effects and intolerance. Overall it appears that in this cohort, 
functional aging is prognostically more important than biological aging.  
Multi-dimensional mortality risk prediction models that consider demographic and lung function 
have a better discriminative ability compared to single predictor variables in patients with ILD;[30, 
32-34] however, these are still suboptimal. There is increasing evidence on the impact of 
comorbidities and accelerated biological aging on survival of patients with ILD,[35, 36] and measures 
of overall health state such as frailty may provide additional prognostic information. Using several 
clinically relevant outcomes, this is the first study showing that functional aging provides prognostic 
information beyond that of commonly used clinical parameters in patients with ILD. A FI of 0.65 is 
the submaximal limit to the proportion of deficits that can be accumulated by elderly community-
dwelling individuals before death is very likely imminent.[19] We similarly show the 99% limit to the 
FI was 0.67 in our younger cohort, consistent with previous observations that the FI limit is 
independent of chronological age. Combined with the reduced medication tolerance in frail patients, 
this finding suggests that patients approaching this submaximal limit should have their goals of care 
carefully reassessed, potentially changing to a palliative strategy that prioritizes symptom 
management rather than continuation of potentially toxic ILD pharmacotherapy. 
The role of aging as a complex biosocial process is increasingly recognised in ILD.[6] To our 
knowledge, this is the first study investigating the clinical importance of functional, chronological, 
and biological aspects of aging in a single cohort of patients with fibrotic ILD, showing that functional 
aging represented by the FI is overall more important than chronological and biological aging for 
prognostication in this population. We explored potential causal pathways mediated by functional 
and biological aging to show that functional aging (i.e., frailty) drives more than 50% of the overall 
age-effect on mortality, whereas biological aging (i.e., aTL) accounts for about 30%. Similarly, 
functional aging was the primary driver of all-cause hospitalisations, while biological aging was the 
main driver of respiratory-related hospitalisations. These findings suggest that respiratory-related 
hospitalisations may be predominantly caused by biological reasons such as ILD worsening (e.g., 
exacerbation, progressive hypoxemia, chronic inflammation catabolic metabolism), whereas the 
reasons for all-cause hospitalisations are usually more complex (e.g., decompensation of the social 
support system). 
Causal mediation analysis requires some assumptions that we addressed in sensitivity analyses, but 
there are no cut-off values to judge the robustness these analyses, and inferences form these 
models need to be confirmed in future studies. We had a relatively small size of some patient 
subgroups which limited the power of subgroup analyses, particularly for telomere length analyses; 
however, our diverse cohort also allows generalization to a larger population of patients with fibrotic 
ILD. Despite the growing awareness of accelerated functional aging as a public health problem, there 
is no agreement on a single definition of frailty.[37] Based on the importance of physical 
functionality for independence in daily living, the Fried frailty phenotype for example includes a 
measure of physical performance.[8] We used the FI, which is a simple measure that does not 
include any physical testing,[4, 18, 38] suggesting that physicians can easily apply many of these 
concepts in patient care. Self-reported tools such as the FI inherently incorporate a patient’s self-
efficacy and perspective on his/her own deficits. This reliance on individual reporting potentially 
introduced heterogeneity to our findings, but our large study cohort nevertheless allowed 
demonstration of statistically significant associations of functional aging with adverse health 
outcomes. 
CONCLUSION  
This novel identification of functional aging as the main driver of quality of life and most age-related 
adverse outcomes in fibrotic ILD emphasizes the importance of recognizing, preventing, and treating 
frailty in this population. These findings suggest the need for integration of the individual functional 
age in clinical decision-making and prognostication in these patients. Future studies are needed to 
evaluate the utility of frailty in clinical decision algorithms and to investigate the effectiveness of 
specific treatment approaches to frailty in patients with fibrotic ILD.  
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TABLES 
Table 1. Baseline characteristics of men and women with fibrotic interstitial lung diseases.  
   Men (n=232) Women (n=308) 
DEMOGRAPHICS   
  Age, years 67.4 (10.2) 62.8 (12.4) 
  Body mass index, kg/m2 28.5 (5.0) 27.3 (6.0) 
  Ever-smoker 128 (55%) 144 (47%) 
  Smoked pack-years* 24.2 (9.5-37) 16.0 (1.8-25) 
ILD SEVERITY   
  FVC, %-predicted 73.0 (19.0) 75.1 (22.1) 
  FEV1, %-predicted 74.9 (18.3) 77.1 (23.3) 
  DLCO, %-predicted 52.9 (18.8) 52.9 (18.7) 
QUALITY OF LIFE   
  SGRQ, total 42.3 (22.8) 43.3 (22.2) 
  SGRQ, activity  53.3 (26.6) 58.1 (23.6) 
  SGRQ, symptom 51.2 (23.2) 48.0 (24.2) 
  SGRQ, impact 32.8 (22.8) 33.8 (23.5) 
 
Data are presented as mean (standard deviation), median (interquartile range), or frequency 
(percentage). 
*in ever-smokers  
Abbreviations: DLCO%, diffusion capacity of the lung for carbon monoxide %-predicted; FEV1, forced 
vital capacity in one second; FVC%, forced vital capacity %-predicted; ILD, interstitial lung disease; 
SGRQ, St. George's Respiratory Questionnaire.  
Table 2. Frailty and telomere length in men and women with IPF and non-IPF fibrotic interstitial lung 
diseases.  
 
Men 
(n=232) 
Women 
(n=308) 
IPF 
(n=100) 
Non-IPF ILD 
(n=440) 
Frailty Index 
0.167 
(0.071-0.286) 
0.238 
(0.120-0.358) 
0.167 
(0.092-0.288) 
0.214 
(0.095-0.333) 
Co-FI 
0.105 
(0.053-0.211) 
0.158 
(0.105-0.263) 
0.111 
(0.097-0.211) 
0.158 
(0.055-0.214) 
I&SC-FI 
0.217 
(0.043-0.384) 
0.304 
(0.087-0.478) 
0.174 
(0.077-0.391) 
0.261 
(0.087-0.435) 
Frail (FI >0.21) 98 (42%) 174 (56%) 39 (39%) 233 (53%) 
Prefrail (FI 0.1-0.21) 58 (25%) 61 (20%) 28 (28%) 91 (21%) 
Absolute telomere length, 
kbp/genome* 
171.1 (45.4) 185.6 (45.8) 163.3 (40.7) 183.2 (46.7) 
 
Data are presented as mean (standard deviation), median (interquartile range), or frequency 
(percentage). 
* Absolute telomere length was calculated for a subgroup of patients with available blood samples 
(sample size: men=87, women=102, IPF=41, non-IPF ILD=148) 
 
Abbreviations: Co-FI, comorbidity Frailty Index; ILD, interstitial lung disease; IPF, idiopathic 
pulmonary fibrosis; I&SC-FI, independence and self-care Frailty Index 
Table 3. Association of frailty with outcomes in fibrotic ILD.   
 Unadjusted analysis Adjusted for age, sex, FVC%, DLCO%, IPF 
Coeff/IRR/HR  
(95%-CI) 
p-value Coeff/IRR/HR  
(95%-CI) 
p-value 
HEALTH-RELATED QUALITY OF LIFE (SGRQ) 
  Frailty Index 7.01 (6.04-7.98) <0.0001 5.83 (4.81-6.84) <0.0001 
  Co-FI 3.49 (2.25-4.72) <0.0001 4.00 (2.79-5.22) <0.0001 
  I&SC-FI 5.25 (4.58-5.92) <0.0001 4.41 (3.68-5.15) <0.0001 
  Frail 21.6 (18.0-25.4) <0.0001 18.0 (14.1-21.7) <0.0001 
Rate of ALL-CAUSE HOSPITALISATIONS 
  Frailty Index 1.03 (1.02-1.04) <0.0001 1.03 (1.01-1.04) <0.0001 
  Co-FI 1.02 (1.00-1.03) 0.01 1.03 (1.01-1.04) 0.003 
  I&SC-FI 1.02 (1.01-1.02) <0.0001 1.02 (1.01-1.03) 0.0001 
  Frail 2.25 (1.38-3.47) <0.0001 1.97 (1.32-3.06) 0.002 
Rate of RESPIRATORY-RELATED HOSPITALISATIONS 
  Frailty Index 1.03 (1.01-1.04) 0.0003 1.02 (1.01-1.04) 0.02 
  Co-FI 1.01 (0.99-1.03) 0.24 1.02 (1.00-1.04) 0.06 
  I&SC-FI 1.02 (1.01-1.03) <0.0001 1.01 (1.00-1.03) 0.03 
  Frail 2.01 (1.25-3.34) 0.003 1.63 (0.79-2.43) 0.09 
TIME TO HOSPITAL DISCHARGE 
  Frailty Index 1.02 (1.00-1.03) 0.005 1.02 (1.00-1.03) 0.009 
  Co-FI 1.01 (0.99-1.02) 0.48 1.01 (0.99-1.03) 0.19 
  I&SC-FI 1.01 (1.01-1.02) 0.001 1.01 (1.00-1.02) 0.004 
  Frail 1.56 (1.55-1.57) 0.01 1.35 (1.32-1.38) 0.048 
TIME TO DEATH 
  Frailty Index 1.03 (1.02-1.04) <0.0001 1.02 (1.00-1.04) 0.02 
  Co-FI 1.01 (0.99-1.02) 0.46 1.02 (0.99-1.04) 0.26 
  I&SC-FI 1.03 (1.02-1.04) <0.0001 1.02 (1.00-1.03) 0.02 
  Frail 2.64 (2.31-3.02) <0.0001 1.77 (1.50-2.08) 0.03 
 
Estimates are per 0.01-unit change in FI, except for health-related quality of life where the 
coefficient represents the change in SGRQ per square root change in FI. Frail is defined as FI >0.21. 
Abbreviations: CI, confidence interval; DLCO%, diffusion capacity of the lung for carbon monoxide 
%-predicted; Co-FI, comorbidity Frailty Index, FVC%, forced vital capacity %-predicted; HR, hazard 
ratio; IPF, diagnosis of idiopathic pulmonary fibrosis; IRR, incidence rate ratio; I&SC-FI, independence 
and self-care Frailty Index; SGRQ, St George’s Respiratory Questionnaire. 
 
  
Table 4. Discrimination of survival models for established mortality risk factors with the addition of 
frailty. 
  FI 
(SE) 
Co-FI 
(SE) 
I&SC-FI 
(SE) 
Unadjusted - 0.679 
(0.028) 
0.528 
(0.032) 
0.709 
(0.026) 
Adjusted     
   - Age, sex 0.648 
(0.028) 
0.718 
(0.028) 
0.650 
(0.028) 
0.756 
(0.026) 
   - Age, sex, FVC, DLCO 0.853 
(0.021) 
0.860 
(0.021) 
0.853 
(0.022) 
0.866 
(0.020) 
   - Age, sex, FVC, DLCO, IPF diagnosis 0.857 
(0.021) 
0.861 
(0.020) 
0.857 
(0.021) 
0.866 
(0.020) 
 
Data shown are optimism-corrected estimates of the Harrell’s C-index, obtained by bootstrap 
resampling with 200 repetitions. 
Abbreviations: DLCO%, diffusion capacity for carbon monoxide %-predicted; Co-FI, comorbidity 
frailty index, FI, frailty index; FVC%, forced vital capacity %-predicted; IPF, diagnosis of idiopathic 
pulmonary fibrosis; I&SC-FI, independence and self-care frailty index. 
  
Table 5. Absolute telomere length and risk of mortality, rate of hospitalisations, and quality of life. 
 Unadjusted analysis Adjusted for age and sex 
 
HR/IRR/Coeff 
(95%-CI) 
p-value 
HR/IRR/Coeff 
(95%-CI) 
p-value 
MORTALITY 
0.92  
(0.80 to1.04) 
0.21 
0.96 
(0.83 to 1.12) 
0.60 
ALL-CAUSE 
HOSPITALISATIONS 
0.94  
(0.88 to 1.01) 
0.06 
0.96 
(0.89 to 1.03) 
 
0.25 
RESPIRATORY-RELATED 
HOSPITALISATIONS 
0.91 
(0.83 to 0.99) 
0.03 
0.99 
(0.98 to 1.01) 
0.19 
TIME TO HOSPITAL 
DISCHARGE 
1.01 
(0.94 to 1.05) 
0.83 
0.99 
(0.92 to 1.06) 
0.70 
HEALTH-RELATED 
QUALITY OF LIFE (SGRQ) 
0.27 
(-0.50 to 1.04) 
0.49 
0.31 
(-0.53 to 1.16) 
0.47 
 
Data shown are per 10kbp/genome change in telomere length. 
Abbreviations: CI, confidence interval; DLCO%, diffusion capacity of the lung for carbon monoxide %-
predicted; Co-FI, comorbidity Frailty Index, FVC%, forced vital capacity %-predicted; HR, hazard ratio; 
IPF, idiopathic pulmonary fibrosis; IRR, incidence rate ratio.  
FIGURES 
Figure 1. Time to hospital discharge in non-frail and frail patients (A), and by tertiles of the Frailty 
Index (B). 
*Survival curves from Cox proportional hazard models adjusting for age and sex. 
Figure 2. Survival in non-frail and frail patients (A) and by tertiles of the Frailty Index (B).  
*Survival curves from Cox proportional hazard models adjusting for age and sex.  
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METHODS 
Measurement of blood leukocyte telomere length  
Absolute telomere length as a marker of biological and cellular aging was measured in peripheral 
blood leukocytes from a sub-cohort of patients with fibrotic ILD. Studies comparing telomere 
attrition in different tissues have shown that telomere length correlates well between blood 
leukocytes and lung parenchyma, and that the rate of telomere attrition is consistent across organ 
systems within individual patients, suggesting that there is an intra-individual synchrony of telomere 
length in somatic tissues.1,2 
A modified version of the Cawthon method for relative measurement of telomere length using 
quantitative real-time polymerase chain reaction and introduction of an oligomer standard was 
applied.3,4 Genomic DNA was isolated from peripheral blood buffy coat using the QIAamp DNA blood 
mini kit (Qiagen, Toronto, Canada). Samples underwent only one freeze-thaw cycle before DNA 
extraction. Standard curves were generated from known quantities of synthesized oligomers of 
telomere DNA [TTAGGG repeated 14 times] and single copy gene (36B4) DNA 
[CAGCAAGTGGGAAGGTGTAATCCGTCTCCACAGACAAGGCCAGGACTCGTTTGTACCCG-
TTGATGATAGAATGGG] (Sigma-Aldrich, St. Louis, MO). The standard curves allow the assessment of 
the sample telomere DNA length based on the ratio of telomere DNA length to 36B4 DNA length. 
DNA from a short telomere cell line (HEK293) and a long telomere cell line (K562, ATCC, Manassas, 
VA) were used as inter-experimental plate controls.5 The ABI ViiA 7 Real Time PCR System (Applied 
Biosystems, Foster City, CA) was used to run samples in triplicate. The telomere lengths measured 
reflect an average length across the population of leukocyte cells included in the sample.  
Expanded statistical methods  
Data structure 
The frailty index (FI) as the main predictor variable, as well as age and other demographic variables 
were collected at every visit; visits within time frames shorter than 6 months were excluded in order 
to avoid overlapping observation periods. Absolute telomere length (aTL) as the secondary predictor 
variable was collected only once in a subset of patients who consented to donation of blood for 
research purposes.  
The primary mortality endpoint was time to the composite of death or lung transplantation based on 
previous observations of comparable disease severity in patients that are about to decease and 
patients undergoing lung transplantation. We performed a pre-specified sensitivity analysis with 
death and lung transplantation as competing risks (i.e., once a patient was transplanted, he or she 
was unable to contribute a subsequent mortality event to the analysis).  
We divided the observation time in intervals defined by the time points of FI and covariate 
assessment in order to account for repeated FI measurement per patient and for time-dependent 
covariates (e.g. FI, age, pulmonary function).6 Other outcomes were assessed within the 6-month 
time periods after every FI assessment: 1) rate of all-cause hospitalisations, 2) rate of respiratory 
related hospitalisations, 3) time to hospital discharge for the patients with hospitalisations, 4) 
occurrence of medication adverse reaction (MAR) for the patients treated with antifibrotic or 
immunosuppressive medications.  
Data analysis 
Descriptive statistics are reported as mean (standard deviation [SD]) or median (interquartile range 
[IQR]). Between group differences were analysed for statistical significance by chi-square or Fisher’s 
exact test for categorical variables and by two-sample t-test or Wilcoxon rank sum test for 
continuous variables. Data were analyzed using R version 3.5.1 (R Foundation for Statistical 
Computing, Vienna, Austria).7  
Mixed effects models  
We applied (generalized) linear mixed models with random intercepts for every patient since 
multiple FI measurements from the same patient cannot be regarded as independent from each 
other. The unadjusted models included FI as a fixed effect. These models were adjusted for potential 
confounders of the effect of FI on adverse health outcomes. We considered confounders with either 
conceptual importance (age, sex) or a statistically relevant relationship to the outcome of interest 
(p<0.1). Consequently, the adjusted models included age, sex, forced vital capacity %-predicted 
(%FVC), diffusion capacity of the lung for carbon monoxide %-predicted (%DLCO), and a diagnosis of 
idiopathic pulmonary fibrosis (IPF) as fixed effects. We used the R package lme4 for these analyses 
with functions lmer and glmer for linear and generalized linear mixed models, respectively.8  
The same data analysis strategy was applied for different outcomes. The rates of all-cause and 
respiratory-related hospitalisations within 6 months were modeled by generalized linear mixed 
models with a Poisson distribution family and a log link function. The probability of MAR within 6 
months from FI assessment was modeled using a generalized linear mixed model with a binomial 
family distribution and a logit link function (i.e. a logistic mixed model). SGRQ was modeled using 
linear mixed models fitted by restricted maximum likelihood (REML) with Satterthwaite’s 
approximations for the degrees of freedom.  
Model specification and standardized residuals were examined, including assessment for normality 
and homoscedasticity, over-dispersion, zero-inflation, and auto-correlation. The R package DHARMa 
was used for these analyses.9 
Survival analysis 
Time to death or lung transplantation and time to hospital discharge were each modeled with Cox 
proportional hazards regression models with intervals of time accounting for time-dependent 
covariates. Unadjusted models for FI and adjusted models including the above covariates were used 
to test the independent association of frailty with mortality. Model performance was measured 
using the Harrell’s C-statistic. The independence between residuals and time (proportional hazards 
assumption) was tested using Schoenfeld residual tests.10  
A prespecified sensitivity analysis with death (without lung transplantation) and lung transplantation 
as competing risks was performed by subdistribution hazard models according to Fine and Gray.11 
The R packages survival and cmprsk were used for these analyses.12,13  
Causal mediation analysis 
A causal mediation analysis (CMA) was performed with the goal to estimate average direct effects of 
chronological age on adverse health outcomes and indirect effects of chronological age mediated by 
either biological age (aTL) or functional age (FI) (Figure S1). We performed a three-step procedure: 
First the mediator models were created by modelling the mediators separately (aTL and FI) as a 
function of the exposure (chronological age), second the outcome models for 2-year survival (logistic 
regression), rate of all-cause and respiratory-related hospitalisations (Poisson regression) were built, 
and third the two models were integrated into the mediation model, which estimates the strength of 
direct and indirect effects for an increase in chronological age by one year.14  
To keep the models parsimonious, no additional covariates were included in the models. 
Assumptions for causal mediation analysis include the absence unmeasured confounding between 
the mediator and the outcome, which is typically untestable. We performed sensitivity analyses in 
order to estimate how strong a confounder would have to be to change the conclusion of the model: 
Unmeasured confounding between the mediator and the outcome leads to correlation between the 
residuals in the mediator and the outcome regression models. We tested the potential strength of 
the correlation between model residuals that would cause the estimated indirect effect to change 
direction.14 CMA was performed with the R mediation package.15  
  
Table S1. Baseline characteristics of patients with CTD-ILD, unclassifiable ILD, IPF and 
hypersensitivity pneumonitis.  
 
Data are presented as mean (standard deviation), median (interquartile range), or frequency 
(percentage). 
*in ever-smokers  
Abbreviations: CTD, connective tissue disease; DLCO%, diffusion capacity of the lung for carbon 
monoxide %-predicted; FEV1, forced vital capacity in one second; FVC%, forced vital capacity %-
predicted; HP, hypersensitivity pneumonitis; ILD, interstitial lung disease; IPF, idiopathic pulmonary 
fibrosis 
 
 
  
   CTD-ILD  
(n=227) 
Unclassifiable 
(n=127) 
IPF  
(n=100) 
HP 
 (n=47) 
DEMOGRAPHICS     
  Sex, men 53 (23%) 72 (57%) 75 (75%) 18 (38%) 
  Age, years 60.1 (12.7) 68.9 (10.6) 70.9 (8.0) 63.9 (10.0) 
  Body mass index, kg/m2 26.3 (5.6) 29.5 (5.3) 27.9 (4.9) 30.8 (5.8) 
  Ever-smoker 101 (43%) 65 (51%) 62 (62%) 25 (53%) 
  Smoked pack-years* 10 (2.25-26.3) 19.5 (9.5-36) 72 (58.8-82.3) 18.1 (7.8-38.2) 
ILD SEVERITY     
  FVC, %-predicted 76.1 (21.5) 73.8 (21.4) 72.0 (17.3) 70.4 (20.6) 
  FEV1, %-predicted 76.5 (22.1) 76.9 (22.1) 76.0 (17.2) 74.1 (21.2) 
  DLCO, %-predicted 54.0 (19.2) 56.6 (19.5) 45.1 (13.7) 53.1 (15.9) 
Table S2. Baseline characteristics of patients with IPF and non-IPF ILDs in the full cohort and the sub-
cohort with blood samples for absolute telomere length measurement available.  
 
 
Data are presented as mean (standard deviation), median (interquartile range), or frequency 
(percentage). 
*in ever-smokers  
Abbreviations: DLCO%, diffusion capacity of the lung for carbon monoxide %-predicted; FEV1, forced 
vital capacity in one second; FVC%, forced vital capacity %-predicted; ILD, interstitial lung disease; 
SGRQ, St. George's Respiratory Questionnaire.  
 Full cohort  Telomere cohort  
 IPF  
(n=100) 
Non-IPF ILD 
(n=440) 
IPF  
(n=41) 
Non-IPF ILD 
(n=148) 
Age 69.7 (8.5) 62.9 (12.6) 68.1 (8.2) 61.6 (11.9) 
Sex, male  75 (74%) 157 (36%) 30 (73%) 57 (39%) 
Body mass index, 
kg/m2 
27.9 (4.9) 27.8 (5.8) 29.0 (4.7) 27.3 (5.4) 
Ever smoker 62 (62%) 210 (48%) 33 (80%) 85 (57%) 
Smoked pack-years 23.5 (13-37) 15 (4-31) 20.0 (12.8-35) 12 (4-25.3) 
ILD SEVERITY  
FVC, %-predicted 72.0 (17.3) 74.7 (21.5) 75.0 (17.0) 76.0 (20.3) 
FEV1, %-predicted 76.0 (17.2) 76.1 (22.1) 79.6 (17.5) 78.0 (20.3) 
DLCO, %-predicted 45.1 (13.7) 54.6 (19.2) 45.3 (13.9) 54.4 (17.4) 
QUALITY OF LIFE     
SGRQ, total 46.9 (23.0) 42.9 (21.8) 50.9 (21.0) 46.4 (18.6) 
SGRQ, activity  63.3 (28.1) 57.2 (25.8) 57.8 (24.4) 55.3 (25.9) 
SGRQ, symptom 48.5 (24.7) 48.5 (23.4) 54.5 (23.9) 46.1 (24.0) 
SGRQ, impact 36.7 (23.1) 32.6 (23.1) 31.3 (17.3) 30.1 (23.1) 
FRAILTY   
Frailty Index  0.167  
(0.092-0.288) 
0.214  
(0.095-0.333) 
0.146  
(0.071-0.262) 
0.181  
(0.043-0.348) 
Co-FI 0.111  
(0.097-0.211) 
0.158  
(0.055-0.214) 
0.105  
(0.105-0.158) 
0.105  
(0.053-0.211) 
I&SC-FI 0.174  
(0.077-0.391) 
0.261  
(0.087-0.435) 
0.174  
(0.043-0.348) 
0.217  
(0.045-0.400) 
Frail (FI >0.21) 39 (39%) 233 (53%) 15 (37%) 70 (47%) 
Prefrail (FI 0.1-0.21) 28 (28%) 91 (21%) 10 (24%) 25 (17%) 
Figure S1. Directed acyclic graph 
The directed acyclic graph illustrates the hypothesized mediation of the effect of chronological age 
on adverse health outcomes by either functional age or biological age.  
Abbreviations: FI, frailty index; aTL, absolute telomere length  
 
  
 
  
Figure S2. Pairwise scatterplots.  
Scatterplots for age, Frailty Index, absolute telomere length, quality of life, and pulmonary function 
tests.  
Abbreviations: DLCO%, diffusion capacity of the lung for carbon monoxide %-predicted; FVC%, 
forced vital capacity %-predicted; SGRQ, St. George's Respiratory Questionnaire.  
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